Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Milvexian in Healthy Chinese Adults
NCT04569695Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of milvexian in thromboembolism (4 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Plasma Concentration of JNJ-70033093 After Single Dose Administration and Plasma Concentration of JNJ-70033093 After Multiple Dose Administration. Started Mar 2021; status: completed.
02
Drugs
milvexian
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT04569695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04569695.